Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index shedding 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.4%.
The iShares Biotechnology ETF (IBB) was up 0.1%.
In corporate news, AstraZeneca (AZN) and its partner Ionis Pharmaceuticals (IONS) said Thursday that a phase 3 trial for eplontersen in people with transthyretin-mediated amyloid cardiomyopathy did not meet the primary efficacy endpoint. AstraZeneca shares fell 5.4%, and Ionis tumbled 24%.
Qiagen (QGEN) is attracting early takeover interest from private equity firms, including EQT AB, Advent and KKR (KKR), with some potential bidders considering offers of at least $50 per share, Bloomberg reported. Qiagen shares jumped past 10%.
MetaVia (MTVA) shares rose 9% after it said Thursday that all active patients in part 3 of its phase 1 trial for obesity drug candidate DA-1726 have completed dose titration and reached their highest planned doses of 48 mg and 64 mg.